Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984028 | 0.86 | MAOA (0.41) | EGFRHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL30983830 | 0.81 | HTT (0.51) | PSMB1EGFRHPGDKDM4EHTT | |
| SCHEMBL30984094 | 0.79 | BACE1 (0.40) | EGFRHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL30983865 | 0.78 | EGFR (0.44) | KDM4CEGFRHPGDKDM4EHTT | |
| SCHEMBL30983904 | 0.75 | KCNH2 (0.38) | KDM4CHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL20715524 | 0.72 | NOS2 (0.50) | PSMB1EGFRHPGDKDM4EALDH1A1 | |
| SCHEMBL30983967 | 0.71 | RECQL (0.42) | EGFRHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL30983979 | 0.70 | ATAD2 (0.46) | EGFRHPGDKDM4EALDH1A1AURKA | |
| SCHEMBL1633210 | 0.67 | PDE5A (0.55) | EGFRHPGDKDM4EHTTALDH1A1 | |
| SCHEMBL30983996 | 0.67 | MAPK1 (0.46) | EGFRHPGDHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PSMB1 358/4885KDM4C 2393/4885EGFR 2432/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | PSMB1 358/4885KDM4C 2393/4885EGFR 2432/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | PSMB1 358/4885KDM4C 2393/4885EGFR 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.